Stoke Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025, revealing significant improvements in its financial performance compared to the same period in 2024. The company achieved a net income of $112.9 million, or $1.90 per diluted share, a remarkable turnaround from a net loss of $26.4 million in the first quarter of 2024. This shift was primarily driven by revenue recognized from the License and Collaboration Agreement with Biogen, amounting to $152.4 million, compared to no revenue from this source in the previous year. Additionally, revenue from the License and Collaboration Agreement with Acadia Pharmaceuticals increased to $6.1 million, up from $4.2 million in the same period in 2024. Research and development expenses rose to $32.7 million, partly due to a one-time $8.2 million sublicense fee associated with the Biogen agreement, compared to $22.4 million in 2024. General and administrative expenses also increased to $14.7 million from $10.2 million, reflecting higher personnel and launch readiness costs. Stoke Therapeutics is advancing its lead investigational medicine, zorevunersen, into Phase 3 development for Dravet syndrome, with the study start anticipated in the second quarter of 2025. The company has achieved regulatory alignment for this global Phase 3 EMPEROR study and continues its strategic collaboration with Biogen to commercialize high-value, disease-modifying medicines for rare genetic diseases while retaining full rights in the United States, Canada, and Mexico. As of March 31, 2025, Stoke Therapeutics had $380.3 million in cash, cash equivalents, and marketable securities, expected to fund operations through mid-2028, including the anticipated launch of zorevunersen.